Dual BET/HDAC inhibition to relieve neuropathic pain: recent advances, perspectives, and future opportunities.
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacological research"
DOI: 10.1016/j.phrs.2021.105901
Abstract: Despite the intense research on developing new therapies for neuropathic pain states, available treatments have limited efficacy and unfavorable safety profiles. Epigenetic alterations have a great influence on the development of cancer and neurological diseases,… read more here.
Keywords: dual bet; activity; neuropathic pain; bet hdac ... See more keywords
Abstract B46: Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.panca19-b46
Abstract: Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis due to largely ineffective therapeutics available for this disease. Recently, inhibitors of bromodomain and extraterminal domain (BET) inhibitors have been shown to have therapeutic efficacy against various… read more here.
Keywords: dual bet; cbp p300; bet cbp; cancer ... See more keywords
Myeloproliferative Neoplasms May Be Sensitive to Dual BET/JAK Inhibition.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2018-002
Abstract: In myeloproliferative neoplasms (MPN) chromatin changes promote NF-κB signaling to drive inflammation. read more here.
Keywords: bet jak; may sensitive; neoplasms may; sensitive dual ... See more keywords